Education
About Us
Working with TipRanks
Follow Us
Grifols SA (GRFS)
NASDAQ:GRFS
Top Page
Grifols SA
(NASDAQ:GRFS)
Select Model
Select Model
Rating:72Outperform
Price Target:
$10.00
▲(13.90% Upside)
Grifols SA's strong financial performance and positive earnings call sentiment are the most significant factors driving the score. While technical indicators suggest potential bearish momentum, the company's robust revenue growth and operational efficiency provide a solid foundation. Valuation is moderate, offering neither a significant discount nor premium.
Grifols SA (GRFS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.88B
Dividend Yield1.56%
Average Volume (3M)710.42K
Price to Earnings (P/E)14.8
Beta (1Y)0.82
Revenue Growth9.45%
EPS Growth167.00%
CountryUS
Employees23,833
SectorN/A
Sector StrengthN/A
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)0.22
Shares Outstanding261,425,100
10 Day Avg. Volume573,323
30 Day Avg. Volume710,421
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)0.83
Price to Sales (P/S)0.68
P/FCF Ratio9.20
Enterprise Value/Market Cap2.56
Enterprise Value/Revenue2.69
Enterprise Value/Gross Profit6.81
Enterprise Value/Ebitda13.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Grifols SA Business Overview & Revenue Model
Company DescriptionGrifols SA is a global healthcare company headquartered in Barcelona, Spain, specializing in the production of plasma-derived therapies and biopharmaceuticals. The company operates primarily in the biotechnology sector, focusing on the development, manufacturing, and marketing of innovative products for the treatment of various medical conditions, including hemophilia, immunodeficiencies, and neurological disorders. Grifols' core products include immunoglobulins, albumin, and clotting factor concentrates, which are derived from human plasma and used in critical care settings and for patients with chronic diseases.
How the Company Makes MoneyGrifols generates revenue primarily through the sale of plasma-derived therapies and other biopharmaceutical products. The company operates a vertically integrated business model, which involves collecting human plasma through its network of donation centers, processing it into therapeutics, and distributing these products to hospitals and healthcare providers worldwide. Key revenue streams include the sale of immunoglobulins, albumin, and clotting factor concentrates, which are essential for treating patients with specific medical needs. Additionally, Grifols has established significant partnerships with healthcare institutions and plasma collection organizations that enhance its supply chain and expand its market reach. The company's ongoing investment in research and development, along with a commitment to innovation, further contributes to its earnings by allowing it to introduce new products and improve existing therapies.
Grifols SA Earnings Call Summary
Earnings Call Date:Nov 04, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Feb 26, 2026
Earnings Call Sentiment Positive
The earnings call highlights Grifols' robust financial performance, with significant revenue growth, improved adjusted EBITDA, and strengthened free cash flow. The company has made progress in deleveraging and gaining market share, particularly in the immunoglobulins franchise. However, challenges such as pricing pressures in China and exchange rate headwinds persist, along with a delay in regulatory approval for fibrinogen in the U.S. Despite these challenges, the overall sentiment leans towards positive, given the strong financial and operational metrics.Q3-2025 Updates
Positive Updates
Strong Revenue Growth
Grifols achieved revenue of EUR 5.5 billion year-to-date, representing a year-over-year increase of 7.7% and 10.5% like-for-like after adjustments, both at constant currency.
Impressive Adjusted EBITDA
Adjusted EBITDA for the third quarter was EUR 482 million, contributing to a year-to-date adjusted EBITDA of EUR 1,358 million, up 11.2% and 17.3% like-for-like, both at constant currency.
Significant Improvement in Free Cash Flow
Year-to-date free cash flow pre-M&A and pre-dividends improved by EUR 257 million year-over-year, reaching EUR 188 million.
Market Share Gains in Immunoglobulins
The immunoglobulins franchise outpaced the market with 18% growth in the quarter and 14% year-to-date, driven by GAMUNEX and XEMBIFY.
Deleveraging Success
Grifols reduced its leverage ratio to 4.2x by the end of Q3, nearly a 1x improvement over the prior year.
Negative Updates
Challenges in China Market
Albumin volumes faced ongoing pricing pressure in China due to government-imposed cost controls, resulting in a contraction of 4.5% for the quarter and 3.9% year-to-date, both at constant currency.
Exchange Rate Headwinds
Revenue and EBITDA levels were negatively impacted by exchange rate fluctuations, although leverage ratio and free cash flow were not significantly affected.
Delay in Fibrinogen AFD Approval in the U.S.
Grifols decided to build additional clinical evidence before seeking regulatory approval for acquired fibrinogen deficiency in the U.S., delaying the market launch.
Company Guidance
During the third quarter of 2025, Grifols demonstrated strong operational and financial performance, achieving revenue of EUR 5.5 billion, marking a year-over-year increase of 7.7% at constant currency. The company reported a third-quarter adjusted EBITDA of EUR 482 million, contributing to a year-to-date adjusted EBITDA of EUR 1,358 million, which is an 11.2% increase from the previous year. Free cash flow pre-M&A and pre-dividends improved significantly by EUR 257 million year over year, totaling EUR 188 million. Despite challenges like exchange rate headwinds and the Inflation Reduction Act, Grifols maintained a leverage ratio of 4.2x by the end of Q3, nearly a 1x improvement from the prior year. The company's immunoglobulins franchise led growth, with the biopharma portfolio growing 10.9% in Q3. Grifols revised its full-year free cash flow guidance to EUR 400-425 million, reflecting the company's focus on financial discipline and resilience amidst a complex global environment.Grifols SA Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
65
Positive
Cash Flow
72
Positive
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Grifols SA Technical Analysis
Positive
8.78
Price Trends
8.98
Positive
9.49
Negative
8.82
Positive
Market Momentum
0.05
Negative
56.52
Neutral
71.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRFS, the sentiment is Positive. The current price of 8.78 is below the 20-day moving average (MA) of 8.91, below the 50-day MA of 8.98, and below the 200-day MA of 8.82, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 56.52 is Neutral, neither overbought nor oversold. The STOCH value of 71.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GRFS.
Grifols SA Peers Comparison
UnderperformOutperform
Sector (―)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | ― | ― | ― | ― | ― | ― | |
78 Outperform | $111.27B | 18.33 | 33.84% | 4.84% | 1.26% | ― | |
78 Outperform | $154.04B | 19.39 | 40.53% | 2.52% | 2.76% | 6407.19% | |
77 Outperform | $178.45B | 25.63 | 81.71% | 3.00% | 11.03% | 65.22% | |
77 Outperform | $98.80B | 13.74 | 35.62% | 3.41% | 5.97% | 128.66% | |
75 Outperform | $116.66B | 12.01 | 8.39% | 4.58% | -9.32% | 120.62% | |
72 Outperform | $7.88B | 14.83 | 6.93% | 1.56% | 9.45% | 167.00% |
* Sector Average
GRFS
Grifols SA
9.11
1.39
18.01%
AMGN
Amgen
331.49
75.34
29.41%
BMY
Bristol-Myers Squibb
54.28
-0.74
-1.34%
GILD
Gilead Sciences
125.19
33.80
36.98%
GSK
GlaxoSmithKline
48.85
16.21
49.66%
SNY
Sanofi
48.32
1.52
3.25%
Grifols SA Corporate Events
Grifols Reports Strong Q3 2025 Financial Performance with Biopharma Growth
Nov 4, 2025
On November 4, 2025, Grifols reported its third-quarter financial results, highlighting a 9.1% year-over-year revenue increase to EUR 1,865 million, driven by the Biopharma business. The company achieved a group profit of EUR 127 million for the quarter, contributing to a 245% year-to-date profit increase. Grifols also improved its leverage ratio to 4.2x and maintained robust liquidity of EUR 1,475 million. The company continues to focus on free cash flow generation and strategic market positioning, with its immunoglobulin franchise showing significant growth.
Grifols Establishes Strategy Committee to Enhance Strategic Governance
Sep 29, 2025
On September 25 and 26, 2025, Grifols, S.A.’s Board of Directors resolved to establish a Strategy Committee to assist in strategic initiatives and developments. The committee, composed of independent, external, and proprietary members, aims to provide advisory support and proposals to the Board. This move is part of Grifols’ efforts to strengthen its strategic governance and enhance its operational efficiency, potentially impacting its market positioning and stakeholder relations.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.